This session includes a focused analysis of emerging evidence in VTE anticoagulation, with particular attention to the landmark COBRRA trial : a pivotal head-to-head comparison of rivaroxaban versus apixaban in patients with acute VTE. The session examines trial design, key outcomes on bleeding risk, and the implications of these findings for anticoagulant selection in everyday clinical practice.